PureTech Health affiliate Karuna has completed a $68 million series B financing round, led by ARCH Venture Partners, with participation from Fidelity Management & Research and others. 18 March 2019
Ahead of the 21-22 March European Council discussion on innovation, industry and competitiveness, the Commission has taken decisive steps to set up a European Innovation Council, committing over 2 billion euros ($2.27 billion) funding in 2019-2020. 18 March 2019
US cost-effectiveness watchdog the Institute for Clinical and Economic Review (ICER) has released a Draft Evidence Report assessing the clinical effectiveness and value of Swiss pharma giant Novartis’ Mayzent (siponimod) for the treatment of secondary progressive multiple sclerosis (SPMS). 15 March 2019
US biopharma CASI has signed a deal with China Resources Guokang Pharmaceuticals (CRGK) for the Chinese company to be the sole distributor of Evomela (melphalan hydrochloride) in the Asian country. 14 March 2019
US biotech Celgene has announced an update for Abraxane (paclitaxel protein-bound particles for injectable suspension; albumin-bound) in the treatment of metastatic triple-negative breast cancer and early stage pancreatic cancer. 14 March 2019
Paris-based Innate Pharma has appointed Jennifer Butler as general manager of its American unit, Innate Pharma US, leading corporate activities to commercialize the novel leukemia therapy Lumoxiti (moxetumomab pasudotox-tdfk). 12 March 2019
WuXi AppTec subsidiary STA Pharmaceutical has agreed terms with fellow Chinese firm Ark Biosciences for a strategic partnership for Chemistry, Manufacturing, and Controls (CMC) development and manufacturing. 6 March 2019
US-based biotech Athenex and Spanish dermatology specialist Almirall have announced positive topline results from two Phase III studies of the experimental ointment KX2-391. 5 March 2019
Taiwan Liposome Company and China’s 3SBio have announced an exclusive partnership to commercialize two liposomal products in mainland China. The products use TLC's NanoX technology platform. 4 March 2019
Shionogi has entered into a collaboration with Nagasaki University in the field of infectious diseases, focused on malaria, which will see the establishment of the Shionogi Infectious Disease Division at the university’s Institute of Tropical Medicine. 28 February 2019
Alder BioPharmaceuticals announced today that the company filed its Biologics License Application (BLA) for eptinezumab with the US Food and Drug Administration. 22 February 2019
Roivant Sciences subsidiary Enzyvant has appointed Rachelle Jacques as chief executive. Ms Jacques was previously senior VP at Alexion and has worked as VP of Shire’s US hematology marketing division. 21 February 2019
Privately-held German companies Boehringer Ingelheim and 3B Pharmaceuticals have signed a multi-year collaboration in peptide-led drug discovery. 21 February 2019
Shanghai-based biotech HaiHe Pharma has partnered with Shijiazhuang-based, government-backed CSPC Pharmaceutical Group to establish a joint venture. 19 February 2019
A recent meeting at the executive of China’s State Council reportedly detailed proposals to lower value added tax (VAT) on both domestically produced as well as imported orphan drugs. 14 February 2019
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Privately-held Ferring Pharmaceuticals has announced the opening of a global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin (nadofaragene firadenovec-vncg). 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
The BioIndustry Association (BIA), in collaboration with the Centre for Process Innovation (CPI), has published a new report on the UK’s mRNA sector. 2 October 2024
Aspen Neuroscience, a private biotechnology company specializing in autologous cell therapies, has announced the opening of a major new facility near its headquarters in San Diego. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024